Vered Stearns - Publications

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 16, 2026

Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer.

Journal: Cancer research

Published: March 19, 2026

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 10, 2026

Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight loss (A-NEW) Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 25, 2026

Development of the cf-MMSP assay for enhanced analytical sensitivity of methylated DNA in breast cancer liquid biopsy.

Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Published: January 19, 2026

Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.

Journal: JAMA network open

Published: November 03, 2025

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

Journal: ESMO open

Published: October 07, 2025

EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).

Journal: Future oncology (London, England)

Published: October 06, 2025

Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) Trial.

Journal: JAMA oncology

Published: August 21, 2025

Cancer systems immunology reveals myeloid-T cell interactions and B cell activation mediate response to checkpoint inhibition in metastatic breast cancer.

Journal: bioRxiv : the preprint server for biology

Published: July 15, 2025

Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumab.

Journal: Research square

Published: June 30, 2025

Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.

Journal: Cancer

Published: April 10, 2025